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Small interfering RNAs (siRNAs), the guides that direct RNA interference (RNAi), provide a powerful tool to reduce the
expression of a single gene in human cells. Ideally, dominant, gain-of-function human diseases could be treated using
siRNAs that specifically silence the mutant disease allele, while leaving expression of the wild-type allele unperturbed.
Previous reports suggest that siRNAs can be designed with single nucleotide specificity, but no rational basis for the
design of siRNAs with single nucleotide discrimination has been proposed. We systematically identified siRNAs that
discriminate between the wild-type and mutant alleles of two disease genes: the human Cu, Zn superoxide dismutase
(SOD1) gene, which contributes to the progression of hereditary amyotrophic lateral sclerosis through the gain of a
toxic property, and the huntingtin (HTT) gene, which causes Huntington disease when its CAG-repeat region expands
beyond approximately 35 repeats. Using cell-free RNAi reactions in Drosophila embryo lysate and reporter assays and
microarray analysis of off-target effects in cultured human cells, we identified positions within an siRNA that are most
sensitive to mismatches. We also show that purine:purine mismatches imbue an siRNA with greater discriminatory
power than other types of base mismatches. siRNAs in which either a G:U wobble or a mismatch is located in the ‘‘seed’’
sequence, the specialized siRNA guide region responsible for target binding, displayed lower levels of selectivity than
those in which the mismatch was located 39 to the seed; this region of an siRNA is critical for target cleavage but not
siRNA binding. Our data suggest that siRNAs can be designed to discriminate between the wild-type and mutant alleles
of many genes that differ by just a single nucleotide.
Citation: Schwarz DS, Ding H, Kennington L, Moore JT, Schelter J, et al. (2006) Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet
2(9): e140. DOI: 10.137/journal.pgen.0020140
Introduction
In the RNA interference (RNAi) pathway, small interfering
RNAs (siRNAs), 21- to 23-nucleotide double-stranded RNAs,
target a corresponding mRNA for post-transcriptional de-
struction. siRNAs act as guides for a protein complex, RISC
(RNA-induced silencing complex), which mediates target RNA
destruction [1–3]. Synthetic siRNAs provide a straightforward
means to knock-down gene expression in vitro in cultured
human cells [4] and in vivo in mice [5–8] and primates [9].
When an siRNA is complementary to its mRNA target, the
siRNA directs endonucleolytic cleavage of the mRNA at a
single phosphate across from nucleotides 10 and 11 of the
siRNA ‘‘guide’’ strand, the strand loaded into the RNA-
induced silencing center (RISC), triggering mRNA destruction
[1,10–12]. Both strands of an siRNA can act as guides
[3,10,13,14], but siRNAs are most effective when speciﬁcally
designed to load the antisense strand into RISC and
concomitantly destroy the sense, or ‘‘passenger,’’ strand
[14,15]. Which siRNA strand serves as the guide reﬂects the
relative thermodynamic stability of the 59 ends of the two
siRNA strands [14,15]. siRNAs that exhibit near absolute
asymmetry, with only one strand of the siRNA capable of entry
into the RISC, are said to be functionally asymmetric [14].
Some mismatches between an siRNA and its target RNA
block target cleavage by RISC [13,16–22]. Thus, siRNAs can
discriminate between mRNAs that differ at a single base-pair,
suggesting the potential application of this mechanism to
suppress mutant genes in dominant human diseases including
amyotrophic lateral sclerosis (ALS) [23–26], Huntington
disease (HD) [27], Alzheimer disease [28], human immunode-
ﬁciency virus infection [29,30], slow channel congenital
myasthenic syndrome [31], spinocerebellar ataxia type 3
[32], sickle cell anemia [33], and cancer [34]. Because siRNAs
to treat these and similar diseases would need to target single
nucleotide polymorphisms (SNPs), their design is limited to
the region surrounding the mutation.
ALS is an age-dependent neurodegenerative disease that
can be caused by sporadic or inherited dominant point
mutations in the Cu, Zn superoxide dismutase gene (SOD1)
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[35]. Point mutations in SOD1 have been linked to the
acquisition of a toxic property by the mutant protein, rather
than loss of the wild-type function of SOD1 in preventing
cellular damage by destroying free oxygen radicals released
from metabolic processes [36]. With many point mutations
clinically identiﬁed, one possible therapy to ameliorate the
symptoms of ALS would be allele-speciﬁc therapy to
selectively eliminate expression of the mutant copy of the
SOD1 gene. Ideally, such a therapy would target only the
mutant allele, because loss of the wild-type gene in mice
causes many abnormalities, including degeneration of motor
neuron axons [37,38], liver cancer, and shortened life span
[39], as well as reduced fertility [40,41]. HD likewise is a
neurodegenerative disorder caused by a dominant, toxic gene
product. HD patients suffer cell death in the cortex and
striatum of the brain, causing motor and cognitive symptoms
[42]. The cause of the disease is an expansion of the CAG
repeat in exon 1 of the huntingtin gene (HTT), which leads to
a protein containing an extended polyglutamine tract [43].
The time of onset of HD correlates with the length of the
expanded CAG repeat [44,45].
To develop a general strategy for the design of single
nucleotide–speciﬁc siRNAs, we examined the effect of
mismatch identity and position on the ability of an siRNA to
discriminate between two target RNAs that differ by only a
single base. As a model system, we used siRNAs that silence the
G85R point mutation in human SOD1, an allele that causes a
familial form of ALS. We then tested the generality of our
ﬁndings by designing siRNAs to discriminate between two
alleles of HTT mRNA that differ at a SNP. Although speciﬁc-
SNP isoforms are not known to correlate with HD, previous
attempts to distinguish between wild-type and disease-causing
HTT alleles using siRNAs targeting the disease-causing CAG-
repeat expansion have proved unsuccessful [46], suggesting
that allele-speciﬁc therapy may be required.
Here, we show that maximal discrimination is achieved
when the siRNA:target RNA pairing is disrupted by a
purine:purine mismatch; little or no discrimination is
achieved by other classes of mismatches. Surprisingly, mis-
matches in the ‘‘seed’’ region of the siRNA—the six-nucleotide
siRNA region that contributes the bulk of target-binding
energy—do not ensure effective single nucleotide discrim-
ination in cultured cells. In contrast, mismatches in the central
and 39 regions of the siRNA provide a high degree of single
nucleotide discrimination, consistent with previous proposals
that target cleavage requires that these regions pair with their
target RNAs to form an A-form RNA:RNA helix [47,48].
Remarkably, a mismatch at siRNA nucleotide 16 provided
more than 4-fold discrimination between two alleles for all ten
siRNA:target RNA pairs examined and robust discrimination
(at least 20-fold) for seven of the ten sequences tested.
Results
A Tiled Set of Functionally Asymmetric siRNAs Targeting
Mutant SOD1
We synthesized a set of 19 siRNAs tiling across the G85R
point mutation of human SOD1 (Figure 1A). The G85R
mutant contains a cytosine at position 323 of the mRNA,
whereas the wild-type mRNA bears a guanosine at that
position. Each siRNA fully matched the mutant SOD1 but
contained a G:G mismatch with wild-type. To ensure that the
antisense strand of each siRNA served as the guide in RISC,
each siRNA had an unpaired, antisense-strand 59 end, a
design strategy that imparts ‘‘functional asymmetry’’ to an
siRNA [14,15]. In vitro RNAi experiments in Drosophila
embryo lysate demonstrated that all 19 siRNAs effectively
targeted their fully matched targets, the mutant G85R allele
of SOD1, allowing us to assess how well each siRNA
discriminated against the wild-type SOD1 allele (Figure 1B).
The importance of this strategy can be seen by comparing the
conventionally designed—i.e., fully paired—siRNA position
11 (P11) from our previous study of allele-speciﬁc siRNAs [23]
with the functionally asymmetric version used here (Figure
1B and 1C). The conventionally designed P11 siRNA showed
considerable discrimination against the wild-type SOD1 allele
(Figure 1C). The functionally asymmetric P11 siRNA (Figure
1B) revealed that the source of this discrimination was the
poor activity of the original siRNA against the fully matched
target, rather than a large difference in its activities against
the two SOD1 alleles.
Analysis of the tiled set of functionally asymmetric siRNAs
showed that the P5, P9, P10, P13, P14, P15, and P16 siRNAs all
discriminated between G85R mutant and wild-type SOD1
(Figure 1B). Additionally, the P12 and P19 siRNAs displayed
some discrimination against the mismatched wild-type target,
Figure 1. Analysis in Drosophila Embryo Lysate of a Tiled Set of siRNAs Targeting Human SOD1
(A) Sequences of the guide siRNA strands used, indicating the site of the G:G mismatch. The third nucleotide from the 39 end of the sense strand of the
siRNA (not shown) was mismatched with the guide, creating an unpaired 59 end to facilitate entry of the guide strand into RISC. For example, where the
first nucleotide of the guide strand was U, the sense strand was changed to C, and vice versa. Where the first guide nucleotide was G, the corresponding
sense strand was designed to be A, and vice versa. The mutant (matched) and wild-type (mismatched) SOD1 mRNA sequences targeted by the siRNAs
are shown below.
(B) Rate of target cleavage in Drosophila embryo lysate of mutant (filled circle) or wild-type target (open circle) for each siRNA in the tiled set.
(C) Comparison of a 59 paired and a 59 unpaired P11 siRNA (B) reveals that the 59 paired siRNA exaggerates the inherent discrimination of this siRNA
between matched and mismatched target RNAs.
DOI: 10.137/journal.pgen.0020140.g001
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Synopsis
First discovered in nematodes, RNA interference (RNAi) has become
an essential tool in the study of mammalian gene function. RNAi
directed by small interfering RNAs (siRNAs), 21 nt, double-stranded
RNAs target complementary mRNAs for destruction. siRNAs can be
introduced into mammalian cells grown in culture, or even
administered intravenously to rodents or primates, where they
repress production of the targeted gene product. Thus, siRNA-
directed RNAi has tremendous potential as a human therapeutic
strategy. Dominant genetic disorders, in which a mutant allele of a
gene causes disease in the presence of a second, normal copy,
might be treated with therapeutic siRNAs, provided that the siRNAs
could be designed to destroy the mutant, disease-causing mRNA,
while leaving the normal mRNA intact. Here, Schwarz and colleagues
describe an experimentally validated strategy for the design of such
siRNAs. Their design strategy should facilitate the design of siRNAs
targeting dominant genetic disorders such as amyotrophic lateral
sclerosis and Huntington disease.
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but these two siRNAs did not show robust silencing of the
perfectly matched mutant target in the cell-free RNAi
reaction, consistent with the idea that an unpaired guide
strand 59 end is not the sole determinant of siRNA efﬁcacy
[15,49]. To provide a more quantitative measure of siRNA
efﬁcacy, we also determined for each siRNA in the tiled set its
initial rate of cleavage in single-turnover reaction conditions
(Figure S1). The initial rate of cleavage reﬂects the concen-
tration of active RISC containing the antisense strand of the
siRNA duplex and the inherent catalytic rate of cleavage of
the targeted sequence but not the rate of product dissocia-
tion from RISC. Four siRNAs exhibited surprisingly slow
initial rates of reaction: P12, P15, P16, and P19. Of these
siRNAs, P12 and P19 also showed a low extent of cleavage
over a longer time course (Figure 1B). In contrast, the P15
and P16 siRNAs performed well over the 2-h time course,
although they showed a slow rate of initial cleavage.
A Stringent Biochemical Test for siRNA Selectivity
While some of the siRNAs in this study exhibited high levels
of discrimination during a 2-h reaction, a more rigorous test
of the ability of an siRNA to discriminate against a
mismatched RNA target is to examine cleavage over a 24-h
period. We performed 24-h cleavage reactions using a high
concentration of siRNA and a low concentration of target
RNA, so as to detect even a small degree of activity of the
siRNA against the mismatched target (Figure 2). Under these
intentionally artiﬁcial conditions, many of the siRNAs which
originally showed complete discrimination against the wild-
type SOD1 RNA target showed detectable levels of cleavage of
the wild-type, mismatched RNA. In contrast, the P12 and P16
siRNAs showed no cleavage of the wild-type target, suggesting
that the mismatch at these positions effectively blocked RISC
activity, under these experimental conditions.
Analysis of Tiled siRNAs in Cultured Human Cells
To what extent does the cell-free analysis using Drosophila
embryo lysate predict the behavior of an siRNA in a human
cell? We assessed the efﬁcacy and discriminatory power of
each siRNA by co-transfecting it into HEK 293T cells with a
plasmid expressing a ﬁreﬂy (Photinus pyralis [Pp]) luciferase
bearing either the relevant region of the wild-type or the
G85R mutant SOD1 sequence cloned into its 39-untranslated
region. Silencing efﬁciency was determined by measuring
ﬁreﬂy luciferase activity, relative to an untargeted Renilla (Rr)
luciferase control, 24 h after transfection with either 2 nM or
20 nM siRNA (Figure 3). Wild-type SOD1 contains a G at
position 323; in the G85R mutant, this position is a C. The
siRNAs were also evaluated using a Pp-luciferase-SOD1 fusion
target containing a uridine residue at position 323 of the
SOD1mRNA sequence. G:U wobbles were previously reported
to be poorly tolerated in the seed sequence of a miRNA-like
siRNA [50], suggesting that G:U mismatches in this region
might provide single nucleotide speciﬁcity, although data in
ﬂies suggest that extensive pairing outside the seed can
compensate for a G:U wobble pair within the seed [51].
The 19 siRNAs examined using the fully matched target
RNA (the G85R mutant SOD1) silenced the reporter by at
least 60%; of these, 15 silenced the reporter by 80% or more
(Figure 3A). When the same set was examined using the
mismatched, wild-type SOD1 reporter, ten of the 19 siRNAs
effectively discriminated against the mismatched target RNA
(Figure 3B). siRNAs P3, P4, P5, P6, P8, P10, P11, P12, P13, and
P16 repressed wild-type reporter expression by less than
40%. Thus, most of the siRNAs that exhibited high levels of
discrimination in the cell-free Drosophila RNAi system also
discriminated in cultured human cells, including siRNAs P5,
P10, P12, P13, and P16.
Next, the same set of siRNAs was co-transfected with a
reporter designed to create a G:U wobble instead of a G:G
mismatch. Only ﬁve siRNAs of the 19 showed effective
discrimination against the wild-type SOD1 reporter (i.e., less
than a 40% reduction in expression) (Figure 3C). In theory,
the ‘‘seed’’ region of an siRNA, which mediates siRNA
binding to a target RNA, should be highly sensitive to
mismatches, but siRNA P3 was the only one of the six siRNAs
to show more than 2-fold allele speciﬁcity when a G:U wobble
was placed within the seed sequence. Rather, mismatches 39
to the seed—siRNAs P8, P11, P13, P14, and P16—best
retained the ability to discriminate against the G:U wobble.
Perhaps seed mismatches are ineffective at destabilizing the
binding of siRNAs bearing extensive complementarity to
their targets, because base-pairs outside the seed region
compensate for mismatches with the seed [51], whereas
mutations 39 to the seed disrupt the A-form helical geometry
required for target cleavage [47,48].
Off-Target Effects Reveal the Strand Specificity of siRNAs
against Mutant SOD1
We tested our siRNA design strategy—unpairing the 59 end
of the antisense strand to promote its incorporation into
RISC—by examining the nature of the ‘‘off-target’’ silencing
proﬁle of each siRNA: the constellation of mRNAs whose
steady-state concentration was decreased in response to that
particular siRNA. Such off-target silencing is thought to
reﬂect seed sequence-directed binding of the siRNA to
mRNAs other than its intended mRNA target [52–54].
Because the siRNA seed sequence is the primary determinant
of siRNA binding, off-target mRNAs contain six-nucleotide
sequences (‘‘hexamers’’) complementary to the seed sequence
of the siRNA strand—sense or antisense—that directed RISC
to destroy them. Thus, determining which strand gives the
greatest enrichment of seed region hexamer matches to the
off-target expression signatures is a measure of which siRNA
strand is preferentially loaded into RISC.
We transfected the siRNAs into cultured human HeLa cells
at 100 nM ﬁnal concentration. This siRNA concentration was
selected to facilitate detection of silencing of unintended
transcripts, in order to reveal the identity of the siRNA strand
loaded into RISC. Total RNA was isolated from the siRNA
transfected cells and analyzed by microarray transcription
proﬁling (Figure 4A and Table 1). Each of the 18 siRNAs that
we were able to evaluate contains a different seed sequence,
so each should have a diagnostic off-target signature. In
addition, this experiment poses a stringent test for siRNA
speciﬁcity, in that (1) the transfected siRNA concentration
was 5 times greater than the highest standard concentration
[55] and 50 times greater than the lower effective concen-
tration (2 nM) used in Figure 3; and (2) endogenous, wild-type
SOD1 is the human mRNA most complementary to each of
the siRNAs that target mutant SOD1. (Human cell lines
expressing the G85R allele of SOD1 are not available.)
Analysis of the off-target mRNAs down-regulated by the 18
siRNAs suggests that eight loaded predominantly their
PLoS Genetics | www.plosgenetics.org September 2006 | Volume 2 | Issue 9 | e1401310
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antisense strand into RISC and ﬁve loaded both strands to
some degree (Table 1). siRNAs P5, P6, and P14 predominantly
loaded their sense strands into RISC, suggesting that for these
three siRNAs, our design strategy was not effective. Both
siRNA P13, which appeared to load both strands into RISC,
and siRNA P14, which loaded predominantly its sense strand,
also showed little activity against their fully matched SOD1
mutant mRNA target (Figure 3A). The low activity of the
antisense strands of these two siRNAs precluded further
analysis of their ability to discriminate between mutant and
wild-type SOD1 mRNA. The microarray data show that three
siRNAs, P8, P9, and P16, triggered no detectable down-
regulation of endogenous wild-type SOD1 (Figure 4A).
Quantitative RT-PCR (qRT-PCR) corroborated the micro-
array analysis (Figure 4B). The P16 siRNA detectably
incorporated only the antisense strand into RISC, whereas
both the P8 and P9 siRNAs loaded both strands into RISC. The
P9 and P16 siRNAs were also highly active in both Drosophila
embryo lysate (Figures 1, 2, and S1) and HEK 293T cells
(Figure 3) against the perfectly matched G85R mutant mRNA.
Notably, all of the siRNAs bearing one G:G mismatch
between the siRNA seed sequence and the endogenous wild-
type SOD1 gene—P2, P3, P4, P5, P6, and P7—targeted the
SOD1 mRNA for destruction at this high siRNA concen-
tration (Figure 4A and 4B). That is, none of these siRNAs
retained its ability to discriminate against wild-type SOD1
when the siRNA was transfected at 100 nM. These data are
consistent with the view that mismatches between the seed
and its target compromise only RISC binding, not catalysis,
and can therefore be overcome by increasing the concen-
tration of the siRNA [48]. However, we cannot exclude the
possibility that, at this high siRNA concentration, other small
RNA-directed mechanisms account for mRNA destruction in
cultured cells and that disrupting seed pairing inherently
blocks Ago2-catalyzed mRNA cleavage.
Nature of the Mismatch Determines Discrimination
Our examination of the tiled set of siRNAs targeting the
G85R SOD1 mutation compared a G:C base-pair with a G:G
mismatch and a G:U wobble. To extend this analysis to other
types of mismatches, we synthesized four siRNAs based on the
P10 siRNA sequence (Figure 1A), placing a G, C, U, or A at
position 10 of the siRNA and constructed four corresponding
reporter constructs expressing Pp-luciferase target RNAs
containing each possible nucleotide across from siRNA
position 10. Combining these four siRNAs with the four
reporter constructs allowed us to examine all possible
Figure 2. Mismatched Target Cleavage after 24-h Incubation in Drosophila Embryo Lysate
To detect low levels of target cleavage, long-time scale reactions were performed with the concentration of RISC greater than that of the RNA target for
those siRNAs (P5, P9, P10, P12, P13, P14, P15, P16, and P19) that showed high levels of discrimination between the matched and mismatched targets in
Figure 1.
DOI: 10.137/journal.pgen.0020140.g002
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position 10 matches and mismatches between the siRNA and
the target. The siRNA sequence used in these studies was
intrinsically asymmetric, silencing a reporter complementary
to the siRNA antisense strand greater than 8-fold more
effectively than a reporter complementary to the siRNA sense
strand (Figure 5A).
Analysis of all possible siRNA:target pairs using 2 nM
siRNA concentration revealed that the strength of pairing
and compatibility with an A-form RNA:RNA helix between
the siRNA and its target at siRNA position 10 correlated with
silencing efﬁcacy. At least one full A-form helical turn is
required for an siRNA to direct cleavage of its RNA target
[47,48]. All of the perfectly matched siRNAs (G:C, C:G, A:U,
and U:A) effectively silenced the reporter, with G:C and C:G
pairs being the most active. Mismatches expected to be well
accommodated in an A-form RNA:RNA helix (pyrimidine:-
pyrimidine, pyrimidine:purine, or purine:pyrimidine) dis-
played intermediate levels of discrimination, whereas
purine:purine mismatches, expected either to destabilize
the helix or to promote a stable, but nonhelical, conforma-
Figure 3. Analysis of Tiled siRNAs against an SOD1-Luciferase Fusion in Cultured Human Cells
(A) Relative firefly luciferase expression for siRNAs (Figure 1A) co-transfected at either 2 nM (gray bars) or 20 nM (white bars) with a reporter plasmid
containing the mutant (matched) SOD1 sequence fused to the luciferase coding sequence.
(B) The same set of siRNAs was analyzed by co-transfection with a reporter plasmid containing the wild-type (mismatched) SOD1 sequence, creating a
G:G clash, or (C) a reporter plasmid encoding a U at the same position, creating a G:U wobble.
Each experiment was performed in triplicate and the data were normalized to luciferase expression measured using a GFP siRNA. Average 6 standard
deviation is shown.
DOI: 10.137/journal.pgen.0020140.g003
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tion, silenced the reporter least (Figure 5B). Increasing the
siRNA concentration increased the extent of silencing—i.e.,
decreased single nucleotide discrimination—for all siRNA:-
target combinations, except for the A:G mismatch, which
maintained its ability to discriminate against the mismatched
reporter at 20 nM siRNA (Figure 5C and 5D).
Analysis of Purine:Purine Mismatches across the siRNA
Sequence
Our data suggest that purine:purine mismatches provide
the highest level of discrimination against mismatched
targets. To corroborate these ﬁndings, we examined the
effect of a purine:purine mismatch at the 19 positions (N1 to
N19) of a single siRNA sequence, the P10 siRNA. For each
purine position in the P10 siRNA, a reporter was constructed
that expressed a Pp luciferase mRNA with a purine at the
corresponding target position. For pyrimidine positions in
the P10 siRNA, a variant siRNA was synthesized substituting a
single pyrimidine with a purine so as to create a purine:pur-
ine clash with the reporter mRNA. Seven siRNAs reduced
expression of the mismatched reporter to less than 40% of
the unsilenced level: N4, N7, N9, N10, N11, N13, and N16
(Figure 6A).
The same method of analysis was applied to the P4 siRNA
Figure 4. Microarray Analysis of 59 Unpaired SOD1 siRNAs
siRNAs from Figure 1A were transfected at 100 nM into HeLa cells and total cellular RNA isolated 24 h later.
(A) Microarray analysis of genes down-regulated by siRNAs. Gene expression profiles were determined by competitive hybridization of amplified mRNA
from siRNA-treated versus mock-treated cells. Shown is a heat map depiction of mRNAs whose expression decreased following siRNA transfection (p ,
0.01, in one or two experiments, except for SOD1). Regulated genes are in columns, experiments in rows. The experiment using P17 was lost. Teal,
genes having decreased mRNA levels compared to mock transfected cells, magenta, genes having increased mRNA levels. The color bar indicates log10
expression ratio transfected/mock transfected cells, 0.6 (teal) to þ0.6 (magenta; i.e., 4-fold). Genes in yellow boxes are representative groups of
transcripts enriched for seed region hexamer matches (see Table 1). The arrow indicates the position of the wild-type SOD1 mRNA, compared to a mock
HeLa cell transfection.
(B) Endogenous SOD1 mRNA levels were determined by quantitative RT-PCR for each siRNA transfection. Shown is the mean 6 standard deviation of
three replicate determinations for each siRNA. Endogenous wild-type SOD1 mRNA is mismatched to the siRNAs used; taller bars imply greater
discrimination against the mismatched target RNA.
DOI: 10.137/journal.pgen.0020140.g004
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(Figure 6B). Luciferase silencing was disrupted the least by
siRNA:target mRNA combinations that placed a single
purine:purine mismatch at siRNA guide position 3, 4, 5, 9,
10, 11, 12, 13, or 16. Intriguingly, seed sequence mismatches—
at positions 3, 4, and 5—were strongly discriminatory for this
siRNA, which has the most thermodynamically stable seed
sequence pairing of all the siRNAs in this study.
For the P4 siRNA scaffold, G:G and A:G mismatches at
position 10 were more selective than A:A or G:A mismatches.
While single nucleotide base-pairs can either stabilize or
destabilize a helix, depending on the identity of both the
mismatch and the adjacent base-pairs [56], the effect of G:G,
A:G, A:A, and G:A mismatches ﬂanked by U:A base-pairs has
not been experimentally determined.
Position 16 Mismatches Generally Discriminate Well
Throughout our analyses—including cell-free RNAi reac-
tions, reporter transfections, and microarray and quantita-
tive-PCR analysis of endogenous mRNA—purine:purine
mismatches at siRNA position 16 consistently discriminated
against the mismatched target. We therefore sought to test
the generality of an siRNA position 16 mismatch as a strategy
for designing allele-speciﬁc siRNA. We synthesized ten
distinct siRNA-mRNA pairs bearing purine:purine mis-
matches: ﬁve targeting an SOD1 point mutation and ﬁve
targeting an HTT SNP. For comparison, a fully matched
siRNA was synthesized for each target. Each pair of
mismatched and matched siRNAs targeted a site inserted
into the 39 untranslated region of Renilla or ﬁreﬂy luciferase
(Table 2). Reporter silencing, relative to a cotransfected
luciferase control, was determined for each siRNA over a
concentration range from 0.001 nM to 20 nM. The siRNA
concentration producing half-maximal silencing (IC50) was
calculated for the match or mismatched siRNAs (Table 2).
For all ten siRNA pairs tested, the IC50 for the siRNA:target
combination with the position 16 mismatch was greater than
that for the fully matched. For seven of the ten siRNA pairs,
the IC50 was at least 20-fold greater for the mismatched
siRNA:target combination.
Discussion
The use of single nucleotide–speciﬁc siRNA to reduce
expression of mutant, disease-causing alleles holds promise
for the treatment of dominantly inherited human diseases
caused by point mutations that lead to a gain of function.
Moreover, human disease alleles often differ from their wild-
type counterparts by SNPs that do not themselves cause the
disease phenotype. By targeting the SNP isoform present in
the disease allele, single nucleotide–speciﬁc siRNA might be
used to reduce selectively expression of the disease-causing
allele without altering expression of the wild-type allele. It is
therefore critical to understand the parameters for designing
siRNAs with optimal discrimination between mRNAs that
differ at a single nucleotide. Previous studies hinted that
purine:purine mismatches between an siRNA and its target
mRNA provide the greatest level of discrimination [23,33,57],
probably reﬂecting greater disruption of the central A-form
helix between the siRNA and mRNA that is required for
siRNA-directed cleavage of the mRNA target [47,48]. Our
systematic analysis here demonstrates the generality of this
principle. Therefore, a point mutation or SNP in which a
purine is changed to a pyrimidine increases the probability
Table 1. Off-Target Analysis Shows that Most of the SOD1 siRNAs Designed to Be Functionally Asymmetric Load the Guide Strand into
RISC
siRNA Antisense Strand Sense Strand Active Strand
Hexamer Rank E-Value Hexamer Rank E-Value
P1 GACUUG 1 3.06 3 108 CAUGCC 3 1.96 3 104 Mixed
P2 ACUUGC 1 1.63 3 1055 ACAUGC .20 3.05 AS
P3 CUUGCG 11 44.3 CAACAU .20 246 AS
P4 UUGCGC 1 1.13 3 105 CCAACA .20 417 AS
P5 UGCGCA .20 142 CCAACA 1 8.84 3 1010 S
P6 GCGCAA .20 1.64 UCCAAC 1 7.02 3 105 S
P7 CGCAAU 1 1.08 3 105 CUCCAA .20 58.2 AS
P8 GCAAUG 4 8.55 3 107 GUCUCC 1 1.65 3 1017 Mixed
P9 CAAUGU 1 5.24 3 1042 GUCUCC 10 3.21 3 1010 Mixed
P10 AAUGUG 1 7.26 3 105 AAGUCU .20 317 AS
P11 AUGUGA 1 2.13 3 105 AAGUCU .20 1.44 3 103 AS
P12 UGUGAC 3 4.31 3 1014 CAAGUC 2 2.1 3 1015 Mixed
P13 GUGACU 1 2.92 3 1028 GCAAGU 2 4.63 3 1019 Mixed
P14 UGACUG .20 146 GCGCAA 1 5.68 3 102 S
P15 GACUGC 1 7.4 3 1047 CGCAAG .20 2.52 3 103 AS
P16 GACUGC 1 1.01 3 1014 UGCGCA .20 599 AS
P18 UGCUGA 1 3.3 3 1057 CAUUGC .20 5.71 AS
P19 GCUGAC 1 1.12 3 1066 ACAUUG .20 5.06 3 103 AS
Microarray analysis was used to identify the mRNAs whose steady-state levels decline upon transfection of an siRNA directed against human SOD1 mRNA into HeLa cells. To determine
which strand of the siRNA duplex was active—i.e., loaded into RISC—down-regulated mRNAs were analyzed for seed hexamer matches to the siRNA guide and passenger strands. 39 UTR
hexamers were ranked by their enrichment in down-regulated mRNAs compared to all mRNAs detected by the microarray. For each strand, the table reports the most significantly
enriched hexamer, its rank (of 4,096 possible hexamers), and its E-value of enrichment. siRNA strands were designated as active if the seed hexamer from that strand ranked in the top 20
hexamers and/or gave E , 103. Mixed indicates that both strands were active. S, sense strand; AS, antisense strand.
DOI: 10.1371/journal.pgen.0020140.t001
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that an siRNA can be designed to discriminate between two
alleles.
Because the last two nucleotides of an siRNA appear not to
contribute to binding speciﬁcity [20] and may in fact slow
RISC-catalyzed target cleavage by slowing the release of
products [48], there are 19 siRNAs that, in theory, could be
speciﬁc for any given point mutation. Here, we show that the
extent of single nucleotide discrimination varies considerably
among the 19 different positions. Using a combination of
cell-free RNAi reactions and cultured human cell transfection
experiments, we found that placing a purine:purine mis-
match at speciﬁc siRNA positions, particularly P10 and P16,
predisposes the siRNA to discriminate effectively between
two alleles that differ at a single nucleotide. P5, P9, P10, P12,
P13, and P16 mismatches consistently discriminated between
two alleles, as tested with three different experimental
strategies. Cell-free RNAi reactions using Drosophila embryo
lysate provided an initial screen for candidate siRNAs capable
of distinguishing between target alleles. Subsequent studies in
cultured human cells assessed these siRNAs for both potency
against the matched target and effective discrimination
against the mismatched target (Figure 3), as well as
determining siRNA strand choice by off-target proﬁling
(Figure 4). In general, mismatches in the 59 seed region of
the siRNA, which is responsible for binding and recognition
[48,50,53,54,58–60], provided only moderate single nucleotide
discrimination, which was overwhelmed by high siRNA
concentrations. In contrast, mismatches 39 to the seed
sequence promoted robust single nucleotide discrimination.
This discrimination was most apparent for mismatches at
positions 10 and 16, but also P9, P12, P13, and P14. In fact, in
each assay used here, a mismatch at siRNA guide position 16
consistently showed high levels of discrimination against a
mismatched RNA target, even at 100 nM siRNA concen-
tration. Intriguingly, the function of plant miRNAs, which
direct siRNA-like cleavage of their mRNA targets, also
appears to be sensitive to position 16 mismatches between
the small RNA and target: no position 16 mismatches and few
G:U wobble pairs have been identiﬁed between plant miRNAs
and their experimentally validated mRNA targets [61]. Thus,
the sixteenth nucleotide of small RNA guides in both plants
Figure 5. Purine:Purine Mismatches Provide the Greatest Discrimination for mRNAs Differing at a Single Nucleotide
(A) The asymmetry of a fully base-paired P10 siRNA was measured using a firefly luciferase reporter containing sense or antisense SOD1 sequences. Even
at high concentrations of siRNA, only the sense target (open squares) was efficiently silenced, compared to the antisense target (filled squares). Thus,
the guide strand of the P10 siRNA was predominantly the antisense strand, consistent with the off-target analysis in Table 1.
(B) All possible single nucleotide pairs were examined for the P10 siRNA. Among the perfectly complementary siRNA:mRNA pairs, a position 10 G:C pair
triggered greater silencing than an A:U pair. Purine:pyrimidine and pyrimidine:pyrimidine mismatches displayed intermediate levels of silencing. The
least silencing, i.e., greatest discrimination, was observed with purine:purine mismatches.
(C) Over a range of concentrations, the pyrimidine:purine mismatches show moderate levels of discrimination compared to the perfectly matched
siRNA:mRNA pair. U:C mismatches, triangles; U:U mismatches, diamonds; U:G mismatches, circles; U:A matched pair, squares.
(D) Purine:purine mismatches cannot be overcome by high concentration of siRNAs and therefore the observed discrimination is not an artefact of low
concentration. A:G mismatches, circles; A:A mismatches, squares; A:C mismatches, triangles; A:U matched pair, diamonds. Mismatches are reported as
siRNA nucleotide:target RNA nucleotide.
DOI: 10.137/journal.pgen.0020140.g005
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and animals may play a biochemically distinct role in
directing target RNA cleavage.
A clear implication of our results is that siRNAs best
discriminate between alleles when the conformation of the
siRNA with the mismatch target acts to block catalysis, rather
than binding, and is therefore less sensitive to siRNA
concentration. Although we do not understand the detailed
biochemical basis for this effect, our data suggest that the
conformation of the helix formed between the small RNA
and its target is monitored by some protein factor—perhaps
even the core RISC protein Argonaute2 itself, the siRNA-
directed RNA endonuclease that destroys the target mRNA.
Materials and Methods
General methods. Preparation of Drosophila embryo lysate and
target RNAs, siRNA annealing, and in vitro RNAi reactions were as
described [12,62,63]. SOD1 mutant and wild-type RNAs were
transcribed from BamHI-linearized plasmids [64] with recombinant
histidine-tagged T7 RNA polymerase. Approximately 5 nM target
RNA and 50 nM siRNA were used in Figure 1; approximately 0.5 nM
target and 100 nM siRNA were used in Figure S1. Gels were dried and
exposed to PhosphorImager (Fuji, Tokyo, Japan) plates, analyzed
using an FLA-5000 PhosphorImager, analyzed, and quantiﬁed using
ImageGuage 3.45 (Fuji), Excel X (Microsoft, Redmond, Washington,
United States), and Igor Pro 5.01 (Wavemetrics, Lake Oswego,
Oregon, United States).
Cell culture, transfection, and luciferase assays. HeLa cells were
propagated and maintained as described [65]. HEK 293T cells were
maintained in Dulbecco’s modiﬁed Eagle medium (Invitrogen,
Carlsbad, California, United States), supplemented with 10% fetal
bovine serum, 100 U/ml penicillin, and 100 lg/ml streptomycin. HTT
sequences were engineered into the 39 UTR of the pRLTK Renilla
luciferase vector (Promega, Madison, Wisconsin, United States) using
55-bp DNA oligonucleotides (IDT, Coralville, Iowa, United States)
designed to create 59 overhangs when annealed, allowing their
insertion into the plasmid XbaI site. Plasmid constructs were veriﬁed
by bidirectional sequencing. SOD1 sequences were cloned into the 39
UTR of the ﬁreﬂy luciferase mRNA (pGL2 control, Promega) into
NdeI and SpeI sites engineered into the plasmid by annealing two 39-
nucleotide DNA oligos and ligating them into the vector. Trans-
fections were carried out using LipofectAMINE 2000 (Invitrogen) in
24-well plates using 0.25 lg of pGL2 ﬁreﬂy luciferase (Promega) and
0.1 lg of Renilla-HTT constructs or in 96-well plates using 2 lg/ml
ﬁreﬂy fusion vector and 0.1 lg/ml Renilla vector. Cells were washed in
13PBS (Invitrogen) and harvested 24 h after transfection in 13passive
Figure 6. Purine:Purine Mismatches Are Tolerated at Some, but Not
Other, siRNA Positions
(A) Purine residues were placed at each position, N1 to N19, along the
P10 siRNA. Targets were constructed so that siRNA:mRNA target pairs
would result in a purine:purine mismatch. Luciferase activity was
measured for each pair.
(B) The P4 siRNA (Figure 1A) was used as a scaffold for the analysis of the
effect of purine:purine mismatches on reporter silencing. Taller bars
correspond to greater single nucleotide discrimination.
DOI: 10.137/journal.pgen.0020140.g006
Table 2. Mismatches at Position 16 Confer a High Level of Single Nucleotide Discrimination
No. siRNA Guide Strand IC50 (nM) Discrimination
Match Mismatch
1 59-UCACAUUGCCCAAGUAUCCdTdT-39 1.0 .20 .20
2 59-UGCCCAAGUCUCCAAGAUGdTdT-39 0.2 .20 .100
3 59-CAGCAGUCACAUUGCGCAAdTdT-39 0.9 .20 .22
4 59-AGUCACAUUGCCCAAGUCUdTdT-39 0.4 .20 .50
5 59-CCAAGUCUCCAACAUGCCUdTdT-39 0.9 .20 .22
6 59-UGAAGUGCACACAGUGGAUGA-39 0.17 0.73 4.3
7 59-UGAAGUGCACACAGUAGAUGA-39 0.1 0.43 4.3
8 59-GAUGAAGUGCACACAGUGGAU-39 0.15 20 133
9 59-GUGCACACAGUGGAUGAGGGA-39 0.23 2 8.6
10 59-AGGGUCAAGAUGACAAUGGAC-39 0.7 . 20 . 28
The first set of siRNAs (No. 1–5) targeted SOD1 mRNA; siRNAs in the second set (No. 6–10) target HTT. All mismatches caused a P16 purine:purine clash: G:G, A:G, or A:A. SOD1 siRNAs were
transfected into HEK 293T cells. For the SOD1 siRNAs No. 1–5, data are the average of four trials. HTT siRNAs were transfected into HeLa cells. For HTT siRNAs No. 6, 7, and 10, the data are
the average of nine trials for siRNAs; for HTT siRNA No. 8, the data are the average of 15 trials; and for HTT siRNA No. 9, the data are the average of six trials. siRNAs targeting SOD1 were
designed to match the disease-causing, mutant sequence and were tested with luciferase reporter plasmids bearing either the mutant or the wild-type sequence. siRNAs targeting HTT
were designed to match a naturally occurring allele of a SNP. Data are normalized to control experiments using an siRNA targeting GFP. When siRNAs did not achieve half-maximal
silencing at the highest tested concentration, the IC50 is reported to be greater than 20 nM. Red text indicates position 16 mismatches.
DOI: 10.1371/journal.pgen.0020140.t002
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lysis buffer (Promega). Luciferase levels were determined using the
Dual Luciferase kit (Promega) and a Veritas Microplate Luminometer
(Turner Biosystems, Sunnyvale, California, United States). Renilla
luciferase/ﬁreﬂy luciferase ratios were normalized to a transfection
with a GFP siRNA (Qiagen, Valencia, California, United States). IC50
values were determined by ﬁtting the data to the Hill equation with n¼
1. For siRNAs in which the half-maximal concentration for silencing
was not reached at the highest concentration tested, IC50 values were
reported as greater than the highest concentration tested.
Microarray and quantitative PCR analysis. HeLa cells were from
the American Type Culture Collection (Rockville, Maryland, United
States). Cells were plated 24 h prior to transfection with Oligofect-
AMINE (Invitrogen). Duplexes were used at a ﬁnal concentration of
100 nM. Cells were transfected in six-well plates and RNA was isolated
24 h following transfection. Total RNA was puriﬁed using the RNeasy
kit (Qiagen). Microarray analysis was performed as described
[53,66,67]. Ampliﬁed cRNA from siRNA-transfected cells was hybri-
dized against cRNA from mock-transfected cells (treated with trans-
fection reagent in the absence of RNA duplex). Ratio hybridizations
were performed with ﬂuorescent label reversal to eliminate dye bias.
Error models have been described previously [53,66,67]. Data were
analyzed using Rosetta Resolver (Rosetta Biosoftware, Seattle,
Washington, United States). mRNA levels were also measured by
qRT-PCR using an ABI PRISM 7900HT Sequence Detection System
and Assays-on-Demand gene expression products (Applied Biosys-
tems, Foster City, California, United States). SOD1 mRNA was
measured using ABI assay No. Hs00533490_A1 and normalized to
b-glucuronidase mRNA, measured using ABI assay No. 4310888E.
Supporting Information
Figure S1. Initial Rates for siRNA-Mediated Cleavage in Drosophila
Embryo Lysate
Reactions were performed using an excess of RISC over substrate
RNA in order to ensure single-turnover conditions. The initial rate of
reaction was determined using data from the ﬁrst 120 s. Filled circles,
mutant siRNA with mutant (matched) target; open circles, mutant
siRNA with wild-type (mismatched) target.
Found at DOI: 10.137/journal.pgen.0020140.sg001 (401 KB PDF).
Accession Numbers
Unprocessed microarray data have been deposited in the NCBI Gene
Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo)
under the accession number GSE5291.
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